Table 2.
Demographic data, MRI features, hormone receptor expression and molecular subtypes of breast cancer
| Characteristics | Number (%) |
|---|---|
| Cases (Number) | 75 |
| Premenopausal | 49 (65.3) |
| Postmenopausal | 26 (34.6) |
| Breast Density on MRI | |
| BIRADS a | 16 (21.3) |
| BIRADS b | 19 (25.3) |
| BIRADS c | 19 (25.3) |
| BIRADS d | 21 (28.0) |
| Background Parenchymal Enhancement | |
| Minimal | 34 (45.3) |
| Mild | 11 (14.7) |
| Moderate | 16 (21.3) |
| Severe | 14 (18.7) |
| Pathology | |
| Invasive Ductal Carcinoma | 62 (82.7) |
| Ductal Carcinoma in Situ | 4 (5.3) |
| Invasive Lobulary Carcinoma | 4 (5.3) |
| Mucinous Carcinoma | 3 (4) |
| Tubulolobulary Carcinoma | 1 (1.3) |
| Papillary Carcinoma | 1 (1.3) |
| Estrogen Receptor | |
| Positive | 60 (20) |
| Negative | 15 (80) |
| Progesterone Receptor | |
| Positive | 53 (70.7) |
| Negative | 22 (29.3) |
| HER2 | |
| Positive | 28 (37.3) |
| Negative | 47 (62.7) |
| Molecular Subtypes | |
| Luminal A | 40 (53.3) |
| Luminal B | 20 (26.7) |
| HER2 Enriched | 8 (10.7) |
| Triple Negative | 7 (9.3) |
BIRADS: Breast Imaging and Reporting Data System; HER2: Human Epidermal Growth Factor 2-neu; MRI: magnetic resonance imaging